As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
15 Analysts have issued a Organon & Co. forecast:
15 Analysts have issued a Organon & Co. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 6,301 6,301 |
2%
2%
|
|
| Gross Profit | 3,468 3,468 |
7%
7%
|
|
| EBITDA | 1,699 1,699 |
3%
3%
|
|
| EBIT (Operating Income) EBIT | 1,357 1,357 |
9%
9%
|
|
| Net Profit | 501 501 |
61%
61%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.
| Head office | United States |
| CEO | Kevin Ali |
| Employees | 10,000 |
| Founded | 2020 |
| Website | www.organon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


